|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.
|
|
2
|
Freeman B, Mamallapalli J, Bian T, Ballas
K, Lynch A, Scala A, Huo Z, Fredenburg KM, Bruijnzeel AW, Baglole
CJ, et al: Opportunities and challenges of kava in lung cancer
prevention. Int J Mol Sci. 24:95392023.
|
|
3
|
Akamine T, Toyokawa G, Tagawa T and Seto
T: Spotlight on lorlatinib and its potential in the treatment of
NSCLC: The evidence to date. Onco Targets Ther. 11:5093–5101.
2018.
|
|
4
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung cancer. 71:3–10.
2011.
|
|
5
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016.
|
|
6
|
Rossi A and Di Maio M: Platinum-based
chemotherapy in advanced non-small-cell lung cancer: Optimal number
of treatment cycles. Expert Rev Anticancer Ther. 16:653–660.
2016.
|
|
7
|
Lopez J, Ramchandani D and Vahdat L:
Copper depletion as a therapeutic strategy in cancer. Met Ions Life
Sci. 19:2019.
|
|
8
|
Bu W, Wang Z, Meng L, Li X, Liu X, Chen Y,
Xin Y, Li B and Sun H: Disulfiram inhibits epithelial-mesenchymal
transition through TGFβ-ERK-Snail pathway independently of Smad4 to
decrease oral squamous cell carcinoma metastasis. Cancer Manag Res.
11:3887–3898. 2019.
|
|
9
|
Li Y, Wang LH, Zhang HT, Wang YT, Liu S,
Zhou WL, Yuan XZ, Li TY, Wu CF and Yang JY: Disulfiram combined
with copper inhibits metastasis and epithelial-mesenchymal
transition in hepatocellular carcinoma through the NF-κB and TGF-β
pathways. J Cell Mol Med. 22:439–451. 2018.
|
|
10
|
Bucci M: Cancer therapy: A path of DSF
destruction. Nat Chem Biol. 14:1072018.
|
|
11
|
Liu X, Wang L, Cui W, Yuan X, Lin L, Cao
Q, Wang N, Li Y, Guo W, Zhang X, et al: Targeting ALDH1A1 by
disulfiram/copper complex inhibits non-small cell lung cancer
recurrence driven by ALDH-positive cancer stem cells. Oncotarget.
7:58516–58530. 2016.
|
|
12
|
Morrison BW, Doudican NA, Patel KR and
Orlow SJ: Disulfiram induces copper-dependent stimulation of
reactive oxygen species and activation of the extrinsic apoptotic
pathway in melanoma. Melanoma Res. 20:11–20. 2010.
|
|
13
|
Liu P, Brown S, Goktug T, Channathodiyil
P, Kannappan V, Hugnot JP, Guichet PO, Bian X, Armesilla AL,
Darling JL and Wang W: Cytotoxic effect of disulfiram/copper on
human glioblastoma cell lines and ALDH-positive cancer-stem-like
cells. Br J Cancer. 107:1488–1497. 2012.
|
|
14
|
Cheriyan VT, Wang Y, Muthu M, Jamal S,
Chen D, Yang H, Polin LA, Tarca AL, Pass HI, Dou QP, et al:
Disulfiram suppresses growth of the malignant pleural mesothelioma
cells in part by inducing apoptosis. PLoS One. 9:e937112014.
|
|
15
|
Skrott Z, Mistrik M, Andersen KK, Friis S,
Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, et al:
Alcohol-abuse drug disulfiram targets cancer via p97 segregase
adaptor NPL4. Nature. 552:194–199. 2017.
|
|
16
|
Tsvetkov P, Coy S, Petrova B, Dreishpoon
M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R,
Spangler RD, et al: Copper induces cell death by targeting
lipoylated TCA cycle proteins. Science. 375:1254–1261. 2022.
|
|
17
|
Zhou B, Guo L, Zhang B, Liu S, Zhang K,
Yan J, Zhang W, Yu M, Chen Z, Xu Y, et al: Disulfiram combined with
copper induces immunosuppression via PD-L1 stabilization in
hepatocellular carcinoma. Am J Cancer Res. 9:2442–2455. 2019.
|
|
18
|
Mi X, Li Z, Yan J, Li Y, Zheng J, Zhuang
Z, Yang W, Gong L and Shi J: Activation of HIF-1 signaling
ameliorates liver steatosis in zebrafish atp7b deficiency (Wilson's
disease) models. Biochim Biophys Acta Mol Basis Dis.
1866:1658422020.
|
|
19
|
Luo F, Lu FT, Cao JX, Ma WJ, Xia ZF, Zhan
JH, Zeng KM, Huang Y, Zhao HY and Zhang L: HIF-1α inhibition
promotes the efficacy of immune checkpoint blockade in the
treatment of non-small cell lung cancer. Cancer Lett. 531:39–56.
2022.
|
|
20
|
Sun S, Guo C, Gao T, Ma D, Su X, Pang Q
and Zhang R: Hypoxia enhances glioma resistance to
sulfasalazine-induced ferroptosis by upregulating SLC7A11 via
PI3K/AKT/HIF-1α Axis. Oxid Med Cell Longev. 2022:78624302022.
|
|
21
|
Koh MY, Spivak-Kroizman T, Venturini S,
Welsh S, Williams RR, Kirkpatrick DL and Powis G: Molecular
mechanisms for the activity of PX-478, an antitumor inhibitor of
the hypoxia-inducible factor-1alpha. Mol Cancer Ther. 7:90–100.
2008.
|
|
22
|
Cui Z, Ruan Z, Li M, Ren R, Ma Y, Zeng J,
Sun J, Ye W, Xu W, Guo X, et al: Intermittent hypoxia inhibits
anti-tumor immune response via regulating PD-L1 expression in lung
cancer cells and tumor-associated macrophages. Int Immunopharmacol.
122:1106522023.
|
|
23
|
Walter B, Gil S, Naizhen X, Kruhlak MJ,
Linehan WM, Srinivasan R and Merino MJ: Determination of the
expression of PD-L1 in the morphologic spectrum of renal cell
carcinoma. J Cancer. 11:3596–3603. 2020.
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
|
|
25
|
Xu R, Zhang K, Liang J, Gao F, Li J and
Guan F: Hyaluronic acid/polyethyleneimine nanoparticles loaded with
copper ion and disulfiram for esophageal cancer. Carbohydr Polym.
261:1178462021.
|
|
26
|
Chen SY, Chang YL, Liu ST, Chen GS, Lee SP
and Huang SM: Differential cytotoxicity mechanisms of copper
complexed with disulfiram in oral cancer cells. Int J Mol Sci.
22:37112021.
|
|
27
|
Hassani S, Ghaffari P, Chahardouli B,
Alimoghaddam K, Ghavamzadeh A, Alizadeh S and Ghaffari SH:
Disulfiram/copper causes ROS levels alteration, cell cycle
inhibition, and apoptosis in acute myeloid leukaemia cell lines
with modulation in the expression of related genes. Biomed
Pharmacother. 99:561–569. 2018.
|
|
28
|
Papaioannou M, Mylonas I, Kast RE and
Brüning A: Disulfiram/copper causes redox-related proteotoxicity
and concomitant heat shock response in ovarian cancer cells that is
augmented by auranofin-mediated thioredoxin inhibition.
Oncoscience. 1:21–29. 2013.
|
|
29
|
Zheng X, Liu Z, Mi M, Wen Q, Wu G and
Zhang L: Disulfiram Improves the Anti-PD-1 Therapy Efficacy by
Regulating PD-L1 expression via epigenetically reactivation of IRF7
in triple negative breast cancer. Front Oncol. 11:7348532021.
|
|
30
|
Falls-Hubert KC, Butler AL, Gui K,
Anderson M, Li M, Stolwijk JM, Rodman SN III, Solst SR,
Tomanek-Chalkley A, Searby CC, et al: Disulfiram causes selective
hypoxic cancer cell toxicity and radio-chemo-sensitization via
redox cycling of copper. Free Radic Biol Med. 150:1–11. 2020.
|
|
31
|
Du H, Chen Y, Hou X, Huang Y, Wei X, Yu X,
Feng S, Wu Y, Zhan M, Shi X, et al: PLOD2 regulated by
transcription factor FOXA1 promotes metastasis in NSCLC. Cell Death
Dis. 8:e31432017.
|
|
32
|
Patsoukis N, Brown J, Petkova V, Liu F, Li
L and Boussiotis VA: Selective effects of PD-1 on Akt and Ras
pathways regulate molecular components of the cell cycle and
inhibit T cell proliferation. Sci Signal. 5:ra462012.
|
|
33
|
Munari E, Zamboni G, Marconi M, Sommaggio
M, Brunelli M, Martignoni G, Netto GJ, Moretta F, Mingari MC,
Salgarello M, et al: PD-L1 expression heterogeneity in non-small
cell lung cancer: Evaluation of small biopsies reliability.
Oncotarget. 8:90123–90131. 2017.
|
|
34
|
Zhao Y, Wang XX, Wu W, Long H, Huang J,
Wang Z, Li T, Tang S, Zhu B and Chen D: EZH2 regulates PD-L1
expression via HIF-1α in non-small cell lung cancer cells. Biochem
Biophys Res Commun. 517:201–209. 2019.
|
|
35
|
Noman MZ, Desantis G, Janji B, Hasmim M,
Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct
target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014.
|
|
36
|
Daniel SK, Sullivan KM, Labadie KP and
Pillarisetty VG: Hypoxia as a barrier to immunotherapy in
pancreatic adenocarcinoma. Clin Transl Med. 8:102019.
|
|
37
|
Barsoum IB, Smallwood CA, Siemens DR and
Graham CH: A mechanism of hypoxia-mediated escape from adaptive
immunity in cancer cells. Cancer Res. 74:665–674. 2014.
|
